Eur Arch Psychiatry Clin Neurosci
August 29, 2026
Esketamine-based treatment, depression-specific metacognitive training, and their combination in treatment-resistant depression: 6-month trajectories of depressive symptoms and rumination in a multicenter observational study.
Eur Neuropsychopharmacol
August 27, 2026
correction
Erratum to "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study" [European Neuropsychopharmacology 107 (2026) 112801].
BMC Anesthesiology
August 26, 2026
Mao Li, Wen Wen, Xiang Wen
Postoperative depression and anxiety are common in elderly patients undergoing joint replacement surgery and may affect recovery. Esketamine has rapid antidepressant effects, but evidence for combined perioperative use remains limited, particularly in elderly patients undergoing joint replacement surgery. This study evaluated the association between combined perioperative esketamine exposure...
Healthcare
August 26, 2026
Mostafa A. Sayed Ali, Palanisamy Amirthalingam, Hanan Alshareef et al.
Background/Objectives: This study evaluated the real-world effectiveness and safety of intranasal esketamine plus oral antidepressants compared with venlafaxine-based oral antidepressant therapy in adults with moderate-to-severe treatment-resistant depression (TRD). Methods: This retrospective cohort study used electronic medical records from a mental health hospital between January 2023 and...
Neuropsychiatrie
August 25, 2026
Nicolas Schmelzle, Katrin Neubacher, Paul L. Plener et al.
BACKGROUND: Depressive symptoms and suicidality are highly prevalent in adolescents with early-onset psychosis (EOP) and often remain refractory to standard treatment. While S‑ketamine is an established treatment for treatment-resistant depression in adults (TRD), its use in primary psychotic disorders remains scarce due to risk of exacerbation of psychotic symptoms. CASE PRESENTATION: We...
Expert Review of Neurotherapeutics
August 18, 2026
Mario Pinzi, Alessandro Cuomo, Maria Beatrice Rescalli et al.
INTRODUCTION: Acute suicidal ideation in major depressive disorder (MDD) is a psychiatric emergency requiring rapid risk assessment, containment, and treatment. Conventional monoaminergic antidepressants have delayed onset, leaving an interval during which severe depressive distress persists. Intranasal esketamine, a rapid-acting N-methyl-D-aspartate receptor antagonist, is approved for MDD...
Der Nervenarzt
August 17, 2026
Stefan Vestring, Katharina Domschke, Claus Normann
Ketamine has been established as an anesthetic agent for decades. Around the turn of the millennium initial clinical studies demonstrated that subanesthetic doses of ketamine can exert antidepressant effects in treatment-resistant depression. These findings established the concept of an effective glutamatergic antidepressant treatment and initiated a paradigm shift. For many years, intravenous...
August 17, 2026
Tychique T. Wasolua, Morgan S. Hardy, Tanner J. Bommersbach et al.
INTRODUCTION: Approximately 30-40% of patients with major depressive disorder fail to respond to conventional antidepressants. Ketamine and esketamine are increasingly used, yet synthesized data on cumulative safety remain limited. This systematic review evaluated long-term safety of both agents. METHODS: MEDLINE, PsycINFO, Embase, and Cochrane Library were searched from inception through...
Journal of Affective Disorders
August 10, 2026
Yves Martins Varela, Patrícia Cavalcanti-Ribeiro, Geovan Menezes de Sousa et al.
BACKGROUND: Ketamine is an effective rapid-acting treatment for treatment-resistant depression (TRD), producing antidepressant effects within hours of administration. Because it induces states of heightened neuroplasticity and psychological openness, psychotherapy may enhance its therapeutic effects. METHODS: This exploratory, nonrandomized, open-label clinical trial evaluated the adjunctive...
The Journal for Nurse Practitioners
August 10, 2026
Tanner Herb, Heeyoung Lee, Prabir Mullick et al.
This quality improvement project examined the impact of shared decision-making–guided music intervention integrated into esketamine treatment on depressive symptoms and quality of life in 10 adults with treatment-resistant depression at a private psychiatric clinic. Over 4 months, patients collaborated with their providers to select and listen to music during each session. Depressive symptoms...